Biannual Injection Reduces HIV Infection Risk
Breakthrough HIV Prevention: Twice-Yearly Injections Show Promise in New Study
A new study offers hope in the fight against HIV, demonstrating the effectiveness of a long-acting injectable medication for preventing infection.
The phase 3 clinical trial, published in the prestigious New England Journal of Medicine, found that biannual injections of Lenacapavir considerably reduced the risk of HIV infection compared to daily oral PrEP (pre-exposure prophylaxis) medication like Truvada.
“This is a major breakthrough,” says Dr.Astrid Berner-Rodoreda of Heidelberg University Hospital in Germany. “Receiving an injection twice a year is much more convenient than taking a daily pill, and it’s less stigmatizing, especially in regions heavily affected by HIV.”
The “purpose 2” study, which concluded early due to its promising results, involved nearly 3,300 HIV-negative participants who engaged in frequent sexual activity. Only two individuals in the Lenacapavir group (approximately 2,200 participants) contracted HIV, compared to nine in the Truvada group (approximately 1,100 participants). This translates to a 96% reduction in HIV risk with Lenacapavir.
Accessibility Remains a Key Challenge
While Lenacapavir has already been approved in the European Union for treating existing HIV infections, its high cost in the United States (approximately $42,000 per year) raises concerns about accessibility, particularly in low-income countries.
Dr. Berner-Rodoreda emphasizes the urgent need to ensure access to this potentially life-saving medication in regions like sub-Saharan Africa, where the burden of HIV is highest.
Long-Term Impact and Resistance Concerns
One potential concern is the development of drug resistance. lenacapavir’s active ingredient can remain in the body for up to a year after the last injection, potentially promoting resistance if not used correctly.
Dr. Max von Kleist of Free University Berlin cautions, “We need to carefully monitor for resistance and ensure responsible use of this powerful new tool.”
despite these challenges, the success of the “Purpose 2” study marks a significant step forward in HIV prevention. Lenacapavir’s long-acting formula offers a promising choice to daily pills, potentially transforming the landscape of HIV prevention and bringing hope to millions worldwide.
A New Era in HIV Prevention: Twice-Yearly Injections Show Remarkable Promise
NewsDirectory3.com – A groundbreaking clinical trial has shed new light on HIV prevention, demonstrating the potent efficacy of lenacapavir, a long-acting injectable medication.
Published in the esteemed New England Journal of Medicine, the ”purpose 2″ study revealed that biannual injections of lenacapavir considerably reduced the risk of HIV infection compared to daily oral PrEP, such as Truvada.
Dr. Astrid Berner-Rodoreda, a leading expert from Heidelberg University Hospital, hailed the findings as a “major breakthrough.” “Receiving an injection twice a year is considerably more convenient and less stigmatizing than daily pills, especially in regions disproportionately affected by HIV,” she explained.
The study, which concluded early due to its extraordinary results, involved nearly 3,300 HIV-negative participants engaging in frequent sexual activity.Only two individuals in the lenacapavir group contracted HIV, compared to nine in the Truvada group, representing a 96% reduction in HIV risk.
While lenacapavir is already approved in the European Union for treating existing HIV infections, its high cost in the United States raises concerns about accessibility, particularly in low-income countries, emphasized Dr. Berner-rodoreda.
Dr. Max von Kleist of Free university Berlin highlighted the importance of long-term monitoring for drug resistance, noting that lenacapavir’s active ingredient can remain in the body for up to a year after the last injection.
Despite these challenges,the “Purpose 2” study heralds a significant advancement in HIV prevention. Lenacapavir’s long-acting formula presents a transformative alternative to daily pills,offering hope to millions worldwide.